The development of the API industry continues to improve, and this field will benefit

【Pharmaceutical Network Market Analysis】In recent years, with the continuous expansion of the production scale of China's API industry, the increasing variety and quantity of generic drugs, and the increase in environmental protection cost pressure, many domestic API companies are increasing investment in this field and increasing their layout
.
It is reported that since the beginning of this year, many local API related companies have reported new
progress in the approval of API products and capacity construction.
The development of the API industry continues to improve, and this field will benefit (Image source: Pharma.
com) A large number of pharmaceutical companies are accelerating the listing of APIs and expanding production capacity For example, Aosikang announced on October 12 that Nanjing Harun Pharmaceutical Co.
, Ltd.
, a wholly-owned subsidiary of the company, recently received the "Notice of Acceptance"
for the marketing registration of nelatinib maleate APIs issued by the State Medical Products Administration.
On October 11, Lifang Pharmaceutical announced that it had received the notice of acceptance of nifedipine API marketing registration; The drug preparation is mainly used clinically for the treatment of hypertension, coronary heart disease, chronic stable angina (exertional angina), etc
.
Prior to this, Huluwa also received the "Chemical API Supplement Application Approval Notice" issued by the State Food and Drug Administration.
.
.
Judging from the continuous listing of APIs of many pharmaceutical companies, the market prospects of APIs are widely optimistic
in the industry.
However, it is worth noting that production capacity is a bottleneck in
front of some enterprises.
It is understood that Jingxin Pharmaceutical has said that the sales revenue of the company's API sector in the first half of 2022 has increased compared with last year, but it is not as fast as the growth rate of the preparation business, mainly because the existing API production capacity is close to the limit
.
It is reported that in order to lay out the API sector, many companies have been actively promoting capacity construction
since the beginning of this year.
On October 6, Jincheng Pharmaceutical said on the investor interaction platform that the proestrel API production line is under construction, and it is expected to be completed by the end of 2022 and trial production
in the first quarter of 2023.
Qianhong Pharmaceutical announced that it signed the "Changzhou Qianhong Pharmaceutical API Production Base Project Contract" with the People's Government of Zhongxiang City, Hubei Province on September 20, 2022, and intends to use its own funds to invest 600 million yuan to build a new API production base project
in Zhongxiang City, Hubei Province.
In addition, Jingxin Pharmaceutical has also mentioned that the new API base in Weifang, Shandong is under construction as planned, and it is expected that some production facilities can be trial-produced
next year.
API enterprises accelerate the expansion of production, the pharmaceutical machinery industry will usher in opportunities The industry believes that from an overall point of view, the high prosperity of China's API industry is attracting a large number of enterprises to further expand the layout and capacity expansion of APIs and pharmaceutical excipients to achieve economies of scale and improve the cost advantage and competitive advantage
of enterprises.
It is worth noting that at the same time, in fact, many raw material companies are also upgrading and upgrading related pharmaceutical equipment to further improve product quality, energy saving and efficiency
.
In the different production links of APIs, a large number of production equipment
with different missions are required.
Such as reaction tanks, fermenters, extraction equipment, sterilization filters, filter presses and so on
.
Therefore, in the context of the accelerated development of API enterprises, pharmaceutical equipment companies will also have huge room for
development.
In fact, at present, in order to meet the needs of related enterprises to upgrade and expand production, many domestic pharmaceutical equipment companies have taken action and begun to create more safe, green and energy-saving, efficient API pharmaceutical equipment and solutions
.
If there is a company, a new type of combined multi-effect water distillation machine
has been developed.
According to reports, this equipment can operate continuously for 240 days, saving 65%
of comprehensive energy in water saving, saving industrial steam, and reducing the sewage pressure of enterprises.
There are also biological deodorization equipment developed by enterprises, and its biological purification process can effectively degrade related pollutants, such as hydrogen sulfide, ammonia, methane, trimethylamine, etc
.
The industry expects that while China's API industry continues to develop in the future, API equipment companies closely related to it will also usher in more opportunities and continue to make new breakthroughs
in high-end fields.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.